Audentes Therapeutics and the University of Pennsylvania announce collaboration
Audentes Therapeutics announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, a rare, inherited, metabolic liver disease. May 04, 2016